Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Group Regulatory News (SAG)

Share Price Information for Science Group (SAG)

Share Price is delayed by 15 minutes
Get Live Data
585.00    0.00 (0.00%)
Bid:
580.00
Ask:
590.00
Spread: 10.00 (1.724%)
Market Cap: £239.60m
SAG Live PriceLast checked at - London Stock Exchange

Intraday Science Group Share Chart

Trading Update, Board Changes and Dividend Policy

18 Oct 2012 07:00

RNS Number : 9506O
Sagentia Group PLC
18 October 2012
 



 

 

18 October 2012

 

Sagentia Group plc

 

("Sagentia", the "Company" or the "Group")

 

Trading Update, Board Changes and Dividend Policy

 

Trading Update

 

Operating performance over the summer period has continued broadly in line with the Board's expectations, as set out in the Interim Report. As a result, the Board anticipates a satisfactory operating outcome for the current financial year, before the one-off cost noted below.

 

The Group's balance sheet remains strong with unaudited shareholders funds at 30 September 2012 of £26.7 million, comprising mainly cash and freehold property, equivalent to approximately 69 pence per share. Net cash at 30 September 2012 was £13.2 million.

 

Board Changes

 

After three years at Sagentia, Brent Hudson, CEO, has decided to leave the company and resign as a director with effect from 31 October 2012. An associated one-off charge will be incurred in the current financial year. Brent has been instrumental in the turnaround of the Group and the Board wish him well for the future.

 

With immediate effect, the current Chairman, Martyn Ratcliffe, has been appointed as Executive Chairman. The Board does not anticipate appointing a plc Board replacement for Mr Hudson but is promoting Mick Withers and Dan Edwards, currently Head of the Medical and Commercial sectors respectively, to Joint Managing Directors of Sagentia Limited, the consultancy operating company.

 

Strategy & Dividend Policy

 

The restructuring in 2010 and 2011 established the required business processes within Sagentia's very talented science and engineering consultancy. As a result, Sagentia today is a successful, profitable business with a blue-chip customer base.

 

The Board continues to explore acquisition opportunities, but remains prudent, particularly in the current economic climate. However, a number of organic business growth opportunities have recently been identified which the Board believe could increase medium term growth. Therefore, whilst the Board will continue to target operating margins towards the upper quartile of comparable companies, in order to pursue these activities, the Board intends to balance the Group's operating margin targets with investment in longer term growth opportunities.

 

The Board has also determined that, subject to shareholder approval at the next Annual General Meeting, it is now appropriate to commence dividend payments. The Board anticipates a single dividend being paid each year.

 

- Ends -

 

For further information:

Sagentia Group plc

Martyn Ratcliffe, Executive Chairman

Tel: +44 (0) 1223 875 200

Neil Elton, Finance Director

www.sagentia.com

 

Numis Securities Limited

Nominated Adviser: Oliver Cardigan / Simon Willis

Corporate Broking: James Serjeant

Tel: +44 (0) 20 7260 1000

 

Media enquiries:

Abchurch

Henry Harrison-Topham

Tel: +44 (0) 20 7398 7702

henry.ht@abchurch-group.com

www.abchurch-group.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGMMMGNNRGZZM
Date   Source Headline
11th Jun 20267:00 amRNSTransaction in Own Shares
10th Jun 20267:00 amRNSTransaction in Own Shares
9th Jun 20267:00 amRNSTransaction in Own Shares
5th Jun 20267:00 amRNSTransaction in Own Shares
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
2nd Jun 20267:01 amRNSTransaction in Own Shares
2nd Jun 20267:00 amRNSTreasury shares issued
1st Jun 20267:00 amRNSTotal Voting Rights
28th May 20267:00 amRNSTransaction in Own Shares
27th May 20267:01 amRNSTransaction in Own Shares
27th May 20267:00 amRNSIssue of share options and PDMR dealing
22nd May 20267:00 amRNSTreasury Shares Issued
22nd May 20267:00 amRNSTransaction in Own Shares
21st May 20267:00 amRNSTransaction in Own Shares
20th May 20261:05 pmRNSResult of Annual General Meeting
20th May 20267:01 amRNSAGM Trading Update and Capital Allocation
20th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
15th May 20267:00 amRNSTransaction in Own Shares
14th May 20267:00 amRNSTransaction in Own Shares
13th May 20267:01 amRNSTransaction in Own Shares
13th May 20267:00 amRNSTreasury Shares Issued
12th May 20267:00 amRNSTransaction in Own Shares
11th May 20267:00 amRNSTransaction in Own Shares
8th May 20267:00 amRNSTransaction in Own Shares
7th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
5th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSTotal Voting Rights
30th Apr 20267:00 amRNSTransaction in Own Shares
29th Apr 20267:00 amRNSTransaction in Own Shares
24th Apr 20267:00 amRNSTransaction in Own Shares
23rd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:01 amRNSNotice of Annual General Meeting
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSTreasury Shares Issued
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.